Aarti Drugs Q1 FY27 slides: EBITDA surges 30% on pricing recovery
Aarti Drugs Limited (BSE:AARTIDRGS) presented its Q1 FY27 investor slides on August 3, 2026, showcasing a robust quarter marked by strong revenue growth and significant margin expansion. The pharmaceutical company reported consolidated revenue of ₹704 crores, up 19% year-over-year, while EBITDA climbed 30% to ₹97 crores.
Reported by 1 outlet — Investing.com · Company News. See all sources ↓
Aarti Drugs Limited (BSE:AARTIDRGS) presented its Q1 FY27 investor slides on August 3, 2026, showcasing a robust quarter marked by strong revenue growth and significant margin expansion. The pharmaceutical company reported consolidated revenue of ₹704 crores, up 19% year-over-year, while EBITDA climbed 30% to ₹97 crores. Despite these strong operational results, the stock declined 1.43% to $416.7, suggesting investor caution about the sustainability of recent pricing gains. The quarter’s performance reflects a broader recovery in the API (Active Pharmaceutical Ingredient) market after several years of pricing pressures.
Read the full report at Investing.com · Company News ↗
Why it matters
A world story we're tracking; its significance and source trust firm up as more outlets confirm it.
- What's the story?
- Aarti Drugs Limited (BSE:AARTIDRGS) presented its Q1 FY27 investor slides on August 3, 2026, showcasing a robust quarter marked by strong revenue growth and significant margin expansion. The pharmaceutical company reported consolidated revenue of ₹704 crores, up 19% year-over-year, while EBITDA climbed 30% to ₹97 crores.
- How widely is it covered?
- 1 outlet, average source rating 5.0/10.
- When was it last updated?
- 3m ago.
How outlets are framing the same story
Here's how each outlet is covering the story — compare their headlines and timing at a glance.
- Coverage card1 outlet1CoverageScouting report
Aarti Drugs Q1 FY27 slides: EBITDA surges 30% on pricing recovery
Sources1TypeCoverageInvesting.com · Company News